Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third-Quarter Indian Results Roundup: Alkem, Neuland, JB, Zydus And Natco

Executive Summary

Several Indian firms have posted growth in their financial third quarters ended 31 December 2018. Alkem’s International sales manage to offset a slide in its domestic turnover, Neuland picks up momentum despite the impact of raw material price increases, while a better product mix in India works in JB’s favor. Zydus obtains a raft of US product approvals and lays out its approach for generics and biosimilars across the globe, while Natco focuses on complex generics in Canada and Brazil.

You may also be interested in...

Manufacturing Roundup – 1 April 2019

Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.

Alvogen Settles With Celgene Over US Revlimid

Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.

EMA Informs On Actions To Prevent Brexit-Related Shortages

A Q&A document has been released by the EMA outlining measures EU authorities are taking to prevent medicine shortages as a result of Brexit. Safety, medicine evaluation, clinical trials and supplies are all topics that are addressed in the text.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts